Study of two experimental drugs for advanced bladder cancer
Treatments studied
Part of Cancer clinical trials.
This study tests two experimental drugs, given alone or together, for advanced urothelial carcinoma (a type of bladder cancer). The goal is to see if they can shrink tumors and slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have been diagnosed with urothelial carcinoma (a type of bladder or urinary tract cancer).
- You must have at least one measurable tumor (a tumor that can be seen on scans).
- You must be able to care for yourself and be up and about (ECOG score of 0 or 1).
- You must have adequate organ function (kidneys, liver, blood cells).
- You must not have had certain cancer treatments within the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called BL-M09D1 for people with advanced bladder cancer (urothelial carcinoma) or other solid tumors that have spread. The goal is to see if the drug can shrink tumors and help people live longer.
This Phase 2 trial studies whether the study medicines SI-B003 alone or together with BL-B01D1 plus SI-B003 can shrink or control advanced cancers that have not responded to standard treatment (or where standard treatment isn’t possible). It also looks at safety and how well the treatment works in people whose cancer can be measured on scans.
This trial tests a new experimental drug combination (BL-B01D1 with a PD-1 immunotherapy) for advanced bladder cancer that has not yet been treated with whole-body therapy. The goal is to see if this combination can shrink tumors and help people live longer without their cancer getting worse.
This trial compares two antibody-drug conjugates (a type of targeted therapy that delivers chemotherapy directly to cancer cells) for advanced urothelial cancer. It aims to find a safer and more effective treatment option for patients with this disease.
This study tests adding new treatments to a standard therapy (enfortumab vedotin and pembrolizumab) for people with advanced bladder cancer that hasn't been treated before. It aims to find out if these combinations are safe and work better.
This trial tests a new drug called SHR-A2102, which is a type of targeted therapy (an antibody-drug conjugate) for advanced urothelial carcinoma (bladder cancer). It may help if your cancer has not responded to standard treatments or if you are starting treatment for advanced disease.
Hear when a new Urothelial Carcinoma (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.